Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

   Recruiting · Phase 3 · Pruritus

   NCT05263206 · Sanofi US Services Inc. · 11 U.S. investigators

   $309,166research payments

2. Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

   Completed · Phase 2 · Cutaneous Squamous Cell Carcinoma

   NCT04154943 · Regeneron Pharmaceuticals, Inc. · 8 U.S. investigators

   $308,458research payments

3. Interventional Study Exploring the Occurrence of Surgical Site Infections.

   Completed · Not applicable · Total Knee Arthroplasty

   NCT06661473 · Molnlycke Health Care Ab · 5 U.S. investigators

   $308,308research payments

4. Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

   Active, not recruiting · Phase 1, Phase 2 · Mantle Cell Lymphoma

   NCT05471843 · Beigene, Ltd. · 11 U.S. investigators

   $307,142research payments

5. Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

   Active, not recruiting · Phase 3 · Myelodysplastic Syndrome (MDS)

   NCT04401748 · AbbVie Inc. · 19 U.S. investigators

   $306,026research payments

6. A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

   Active, not recruiting · Hemophilia B

   NCT05568459 · Regeneron Pharmaceuticals, Inc. · 12 U.S. investigators

   $305,992research payments

7. A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

   Completed · Phase 2 · Non-small Cell Lung Cancer

   NCT04623775 · E.r. Squibb & Sons, L.l.c. · 14 U.S. investigators

   $305,835research payments

8. International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

   Recruiting · Gaucher Disease

   NCT00358943 · Sanofi US Services Inc. · 47 U.S. investigators

   $304,381research payments

9. Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

   Completed · Phase 2 · Chronic Obstructive Pulmonary Disease

   NCT05326412 · Sanofi US Services Inc. · 9 U.S. investigators

   $304,380research payments

10. Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

    Active, not recruiting · Phase 1, Phase 2 · Frontotemporal Dementia

    NCT04408625 · Eli Lilly and Company · 3 U.S. investigators

    $303,696research payments

11. Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

    Terminated · Phase 2 · SARS-CoV-2

    NCT05584202 · ModernaTX, Inc. · 28 U.S. investigators

    $302,829research payments

12. Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

    Active, not recruiting · Phase 2 · Yellow Fever

    NCT04942210 · Sanofi Pasteur Inc. · 12 U.S. investigators

    $301,147research payments

13. A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

    Terminated · Phase 1 · Advanced Cancer

    NCT06540066 · Beone Medicines USA, Inc. · 4 U.S. investigators

    $300,126research payments

14. A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

    Completed · Phase 3 · Lichen Simplex Chronicus

    NCT06687980 · Sanofi US Services Inc. · 12 U.S. investigators

    $299,850research payments

15. A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System

    Completed · Phase 4 · Non-Surgical Fat Reduction

    NCT07122583 · AbbVie Inc. · 5 U.S. investigators

    $298,876research payments

16. A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

    Completed · Phase 1 · Renal Impairment

    NCT05940402 · AbbVie Inc. · 5 U.S. investigators

    $296,896research payments

17. Lu AF28996 in Participants With Parkinson's Disease (PD)

    Completed · Phase 1 · Parkinson Disease

    NCT04291859 · H. Lundbeck A S · 8 U.S. investigators

    $296,334research payments

18. A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

    Active, not recruiting · Phase 1 · Leiomyosarcoma

    NCT06308419 · Aadi Bioscience, Inc. · 1 U.S. investigator

    $295,356research payments

19. A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

    Active, not recruiting · Phase 2 · Advanced Non-Small Cell Lung Cancer

    NCT05557591 · Regeneron Pharmaceuticals, Inc. · 11 U.S. investigators

    $294,151research payments

20. CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

    Terminated · Phase 2 · Melanoma

    NCT04698187 · Regeneron Pharmaceuticals, Inc. · 2 U.S. investigators

    $293,891research payments

21. Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

    Terminated · Phase 3 · Crohn Disease

    NCT03440372 · Celgene Corporation · 17 U.S. investigators

    $292,597research payments

22. Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease

    Recruiting · Phase 4 · Common Variable Immunodeficiency

    NCT05193552 · Csl Behring · 1 U.S. investigator

    $291,699research payments

23. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

    Completed · Phase 1, Phase 2 · Influenza Immunization

    NCT05624606 · Sanofi Pasteur Inc. · 12 U.S. investigators

    $291,444research payments

24. A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

    Recruiting · Phase 1 · Plasma Cell Myeloma Refractory

    NCT06630806 · Genzyme Corporation · 5 U.S. investigators

    $289,344research payments

25. Open-Label Extension Study of Trofinetide for Rett Syndrome

    Terminated · Phase 3 · Rett Syndrome

    NCT04776746 · Acadia Pharmaceuticals Inc · 5 U.S. investigators

    $286,888research payments

26. A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

    Completed · Phase 3 · Generalized Myasthenia Gravis

    NCT06471361 · UCB SA · 7 U.S. investigators

    $286,751research payments

27. Tumor-induced Osteomalacia Disease Monitoring Program

    Active, not recruiting · Tumor-induced Osteomalacia (TIO)

    NCT04783428 · Ultragenyx Pharmaceutical Inc. · 5 U.S. investigators

    $286,504research payments

28. Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Active, not recruiting · Phase 2 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT04458610 · Beigene, Ltd. · 1 U.S. investigator

    $285,675research payments

29. Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

    Recruiting · Phase 2, Phase 3 · Urothelial Cancer

    NCT07129993 · Daiichi Sankyo Inc. · 21 U.S. investigators

    $285,427research payments

30. Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

    Terminated · Not applicable · Heart Failure (for Example, Fluid Overload)

    NCT05318105 · Nuwellis, Inc. · 16 U.S. investigators

    $285,292research payments

31. Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

    Active, not recruiting · Not applicable · Thoracoabdominal Aortic Aneurysm

    NCT03728985 · W. L. Gore & Associates, Inc. · 40 U.S. investigators

    $285,147research payments

32. Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

    Active, not recruiting · Phase 2 · Colitis Ulcerative

    NCT05588843 · Genzyme Corporation · 11 U.S. investigators

    $285,083research payments

33. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

    Recruiting · Phase 1, Phase 2 · Metastatic Hepatocellular Carcinoma

    NCT06427941 · Beone Medicines Ltd. · 2 U.S. investigators

    $284,725research payments

34. First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

    Completed · Phase 1, Phase 2 · Relapsed Multiple Myeloma

    NCT04083534 · Regeneron Pharmaceuticals, Inc. · 7 U.S. investigators

    $284,506research payments

35. A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

    Recruiting · Phase 1 · Head and Neck Cancer

    NCT04722523 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $284,148research payments

36. Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

    Terminated · Phase 2 · Amyotrophic Lateral Sclerosis

    NCT05349721 · Ptc Therapeutics, Inc. · 13 U.S. investigators

    $284,002research payments

37. Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

    Active, not recruiting · Phase 2 · Hepatocellular Carcinoma

    NCT05822752 · AbbVie Inc. · 10 U.S. investigators

    $282,470research payments

38. A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

    Completed · Phase 1, Phase 2 · Alpha1-Antitrypsin Deficiency

    NCT04722887 · Grifols Therapeutics LLC · 6 U.S. investigators

    $281,896research payments

39. A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

    Completed · Phase 3 · Adult Growth Hormone Deficiency

    NCT05171855 · Ascendis Pharma Endocrinology Inc · 13 U.S. investigators

    $281,882research payments

40. RevCore for In Stent Thrombosis

    Recruiting · In-stent Thrombosis

    NCT06394739 · Stryker Corporation · 13 U.S. investigators

    $281,590research payments

41. A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

    Active, not recruiting · Phase 3 · Moderate to Severe Plaque Psoriasis

    NCT06425549 · UCB SA · 7 U.S. investigators

    $281,120research payments

42. A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

    Completed · Phase 2 · Cytomegalovirus Infection

    NCT04975893 · ModernaTX, Inc. · 6 U.S. investigators

    $281,001research payments

43. A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

    Active, not recruiting · Phase 3 · Ulcerative Colitis

    NCT03519945 · Eli Lilly and Company · 24 U.S. investigators

    $279,669research payments

44. DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

    Completed · Phase 3 · Breast Cancer

    NCT03529110 · Daiichi Sankyo Inc. · 17 U.S. investigators

    $279,354research payments

45. A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

    Completed · Phase 2 · Seizures

    NCT04244175 · AbbVie Inc. · 33 U.S. investigators

    $278,347research payments

46. Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

    Active, not recruiting · Phase 1 · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

    NCT01479842 · AbbVie Inc. · 1 U.S. investigator

    $278,180research payments

47. A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

    Terminated · Phase 1, Phase 2 · Multiple Myeloma

    NCT03374085 · Celgene Corporation · 6 U.S. investigators

    $276,453research payments

48. A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

    Completed · Phase 3 · Metastatic Breast Cancer

    NCT02163694 · AbbVie Inc. · 2 U.S. investigators

    $276,413research payments

49. DS-3201b in Participants With Lymphomas

    Active, not recruiting · Phase 1 · Lymphoma, Malignant

    NCT02732275 · Daiichi Sankyo Inc. · 8 U.S. investigators

    $275,418research payments

50. A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

    Recruiting · Phase 2 · Bipolar I Disorder

    NCT06696755 · AbbVie Inc. · 19 U.S. investigators

    $275,262research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.